Allchem Lifescience IPO Details
MAINBOARD
Allchem Lifescience IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
The Lead Managers for Allchem Lifescience IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Emkay Global Financial Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Allchem Lifescience Limited DRHP.
Allchem Lifescience IPO Details
Allchem Lifescience IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Allchem Lifescience IPO Reservation
Promoter Holding
Documents
Allchem Lifescience IPO Valuations
Allchem Lifescience Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 246.3 | 224.65 | 186.68 | 124.02 |
| Total Income | 78.53 | 138.07 | 106.03 | 109.42 |
| Profit After Tax | 10.89 | 23.41 | 17.99 | 14.14 |
| Net Worth | 90.74 | 79.89 | 56.49 | 38.58 |
| Reserves and Surplus | 86.49 | 75.64 | 52.24 | 35.08 |
| Total Borrowing | 106.9 | 104.97 | 97.17 | 49.53 |
| Amount in ₹ Crore | ||||
About Allchem Lifescience IPO
Incorporated in 2017, Allchem Lifescience Limited is manufacturer of active pharmaceutical ingredient (API) intermediates and specialty chemicals. The company focuses on producing key starting materials (KSMs), generic API intermediates, and speciality chemicals to cater to both domestic and international pharmaceutical and chemical industries.
Business Verticals
Allchem Lifescience Limited operates through two primary business segments:
- Manufacturing API Intermediates
- API intermediates are essential chemical compoundsused in the production of active pharmaceutical ingredients (APIs) and finished drugs.
- These intermediates serve as crucial building blocks in synthesis processes, undergoing transformations that result in the final API or drug formulation.
- Specialty or Fine Chemicals
- Specialty chemicals, also known as performance chemicals, are custom-designed substances for specific applications.
Product Portfolio & Capabilities
Allchem Lifescience Limited has developed the capability to manufacture 263 products, demonstrating expertise in various organic chemical compounds and advanced chemistries.
Clientele
The company serves a diverse range of domestic and international customers, including:
- Indian Clients: Alembic Pharmaceuticals Limited, Indoco Remedies Limited, Megafine Pharma (P) Limited, Micro Labs Limited, MSN Laboratories Private Limited, Neogen Chemicals Limited, Neuland Laboratories Limited, Unichem Laboratories Limited, Vasudha Pharma Chem Limited, and more.
- International Clients: Bond Chemical Limited, Chemosyntha BV, Cohance Life Sciences Limited, Egene Co Limited, Hattori Corporation, Huaian Jiamu Biotechnology Co. Limited, Moehs Iberica, S.L., Nagase India Private Limited, Olon Active Pharmaceutical Ingredients India Private Limited, and Vivatis Pharma GmbH.
Manufacturing & Infrastructure
- Manufacturing Facility: Located in Village Manjusar, Vadodara, Gujarat
- Total Equipment Capacity (as of December 31, 2024): 1,133.50 KL
- Permanent Employees (as of December 31, 2024): 430
Strength Of Allchem Lifescience IPO
Risk Of Allchem Lifescience IPO
Objectives Allchem Lifescience IPO
1. Repayment or pre-payment, in full or in part, of certain of the outstanding borrowings availed by the Company.
2. General corporate purposes
Company Contact Details
Allchem Lifescience Ltd.
Block No. 1088/B/P, 1088-A, Lamdapura Road,
Village Manjusar,
Tal-Savli
Vadodara, Gujarat, 391775
Phone: +91-9574722211
Email: investor@allchemlifescience.com
Website: http://www.allchemlifescience.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Allchem Lifescience IPO - FAQs
The Allchem Lifescience IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.